In contrast, Hoxha et al. showed that AAA could be an early marker associated with poor clinical response in 58 rheumatic patients treated with ADA; however, ANA positivity was not significantly different between AAA-positive and negative groups [13]. The gene discussed is BTG3; the disease is triple-A syndrome.